RT Journal Article
SR Electronic
T1 SARS-CoV-2 titers in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.15.20117747
DO 10.1101/2020.06.15.20117747
A1 Wu, Fuqing
A1 Xiao, Amy
A1 Zhang, Jianbo
A1 Moniz, Katya
A1 Endo, Noriko
A1 Armas, Federica
A1 Bonneau, Richard
A1 Brown, Megan A
A1 Bushman, Mary
A1 Chai, Peter R
A1 Duvallet, Claire
A1 Erickson, Timothy B
A1 Foppe, Katelyn
A1 Ghaeli, Newsha
A1 Gu, Xiaoqiong
A1 Hanage, William P
A1 Huang, Katherine H
A1 Lee, Wei Lin
A1 Matus, Mariana
A1 McElroy, Kyle A
A1 Nagler, Jonathan
A1 Rhode, Steven F
A1 Santillana, Mauricio
A1 Tucker, Joshua A
A1 Wuertz, Stefan
A1 Zhao, Shijie
A1 Thompson, Janelle
A1 Alm, Eric J
YR 2020
UL http://medrxiv.org/content/early/2020/07/06/2020.06.15.20117747.abstract
AB Current estimates of COVID-19 prevalence are largely based on symptomatic, clinically diagnosed cases. The existence of a large number of undiagnosed infections hampers population-wide investigation of viral circulation. Here, we use longitudinal wastewater analysis to track SARS-CoV-2 dynamics in wastewater at a major urban wastewater treatment facility in Massachusetts, between early January and May 2020. SARS-CoV-2 was first detected in wastewater on March 3. Viral titers in wastewater increased exponentially from mid-March to mid-April, after which they began to decline. Viral titers in wastewater correlated with clinically diagnosed new COVID-19 cases, with the trends appearing 4-10 days earlier in wastewater than in clinical data. We inferred viral shedding dynamics by modeling wastewater viral titers as a convolution of back-dated new clinical cases with the viral shedding function of an individual. The inferred viral shedding function showed an early peak, likely before symptom onset and clinical diagnosis, consistent with emerging clinical and experimental evidence. Finally, we found that wastewater viral titers at the neighborhood level correlate better with demographic variables than with population size. This work suggests that longitudinal wastewater analysis can be used to identify trends in disease transmission in advance of clinical case reporting, and may shed light on infection characteristics that are difficult to capture in clinical investigations, such as early viral shedding dynamics.Competing Interest StatementMM and NG are cofounders of Biobot Analytics. EJA is advisor to Biobot. NE, CD, KF, and KAM are employees at Biobot. All these authors hold shares in the company.Funding StatementThis work was supported by the Center for Microbiome Informatics and Therapeutics and Intra-CREATE Thematic Grant (Cities) grant NRF2019-THE001-0003a to JT and EJA; National Institute on Drug Abuse of the National Institutes of Health award numbers K23DA044874; and R44DA051106 to MM and PRC, Hans and Mavis Psychosocial Foundation funding, and e-ink corporation funding to PRC; funding from the Morris-Singer Foundation and NIH award R01AI106786 to WPH; funds from the Massachusetts Consortium on Pathogen Readiness and China Evergrande Group to TBE, PRC, MM, and EJA; funding from the Singapore Ministry of Education and National Research Foundation through an RCE award to Singapore Centre for Environmental Life Sciences Engineering (SCELSE) to SW and JT; and a National Institute of General Medical Sciences of the National Institutes of Health award, number R01GM130668, to MS. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.